SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is trending amidst claims of AI-powered utility and deep integration within the Coinbase Base ecosystem, igniting a fervent community debate between those predicting a parabolic ascent and others warning of a rapid pump-and-dump.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending due to a significant price dip that has ignited a fierce debate, with many viewing it as either a prime accumulation opportunity or a "pump and dump" heading for lower valuations. Community discussion heavily centers on the progression of the Clarity Act, which supporters believe will solidify XRP's institutional adoption despite current market volatility.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is gaining attention due to new integrations like Kalshi and Orbs, alongside significant whale investments and rapid DApp adoption bolstering its utility and liquidity. The community is bullish on its groundbreaking EVM-compatible Layer 1 technology and parallel processing, with many actively 'buying the dip' and 'staking' for long-term growth despite broader market volatility and debates around future token dilution.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as competitor Cotti Coffee ends aggressive pricing, setting the stage for improved profitability, while investors keenly compare its hyper-growth and superior fundamentals against Starbucks, fueling community discussion around its rapid global expansion and the anticipated uplisting from the OTC market.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending following Google DeepMind's unveiling of its Genie 3 world model, an AI tool that generates interactive 3D environments from text, sparking intense debate over its competitive implications. While some investors fear Google's AI signals obsolescence for existing game engines, many others consider the sell-off an overreaction, arguing Genie 3 is a complementary tool that could ultimately boost demand for Unity's robust development platform.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after its competitor Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, which the community views as a significant tailwind for Xeris's Recorlev to gain market share and accelerate revenue growth. Investors are also discussing the company's strong preliminary Q4 revenue and the anticipated Phase 3 trial for its multi-blockbuster potential drug, XP-8121.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is seeing a sharp downturn following a hawkish Fed Chair nomination and a broader tech sell-off, leading to divided community sentiment. While many express bearish outlooks and concerns over market manipulation, others view the current dip as a prime accumulation opportunity, citing strong ETF inflows and potential capital rotation from falling precious metals.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is trending as institutional adoption accelerates, driven by its new Grayscale ETF and growing utility for real-world asset tokenization and cross-chain interoperability. The community is actively debating its long-term potential as a foundational crypto asset, despite some recent price volatility.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Intensifying speculation regarding an improved acquisition offer from Sanofi, reportedly after a rejected initial bid, is driving conversation around Ocular Therapeutix. The community is highly optimistic about upcoming Phase 3 data for AXPAXLI in wet AMD and a recent high-profile hire, fueling expectations for a substantial premium or strong independent commercialization despite recent price volatility.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

Bluebird Bio, Inc. (BLUE) said on Wednesday that global investment firms Carlyle (CG) and SK Capital Partners have agreed to purchase all its outstanding shares and take the company private for $5 per share upfront.Under the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bluebirdbio.com/news-releases/news-release-details/carlyle-sk-capital-partners-and-bluebird-bio-amend-merger">amended</a> agreement, Bluebird stockholders can elect to receive either $3 per share in cash plus a contingent value right (CVR) of $6.84 per share in cash payable upon achievement of a net sales milestone or $5 per share in cash.The upfront payment of $5 represents a 51% premium to Bluebird’s closing price of $3.31 on Tuesday.Shares of the company traded over 50% higher on Wednesday morning.Gene therapy maker Bluebird first entered a definitive agreement with Carlyle and SK Capital in February. As per the original agreement, stockholders had only one option of receiving $3.00 per share in cash plus a CVR of $6.84 per share.Bluebird said the amended agreement allows an alternative for stockholders who would prefer greater upfront cash consideration instead of the potential upside of the CVR.The Bluebird board of directors recommended that shareholders tender their shares in support of the transaction by 11:59 p.m., New York City time, on May 29, 2025, following which the tender offer would expire.The company said that unless a majority of stockholders tender their shares, Bluebird is at significant risk of defaulting on its loan agreements with Hercules Capital, and it is extremely unlikely that stockholders would receive any consideration for their shares in a bankruptcy or liquidation.On Stocktwits, retail sentiment around Bluebird rose within the ‘bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:633/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_14_at_10_22_02_AM_png_1451c7b7eb.webp" alt="BLUE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on May 14, 2025 | Source: Stocktwits" width="633" height="60"><figcaption>BLUE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on May 14, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLUE">BLUE stock</a> is down by about 43% this year and about 77% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dynatrace-technology-q4-2025-earnings/chiqru4RbNS">Dynatrace Stock Rises On Upbeat Q4 Earnings, Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Bluebird bio logo is seen on a smartphone and a pc screen in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Bluebird Bio Stock Soars On Higher Upfront Payment Under Amended Merger Deal: Retail Gets More Bullish 

The upfront payment of $5 represents a 51% premium to Bluebird’s closing price of $3.31 on Tuesday.

Equity

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

BLUE
Bluebird bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLUE News

BLUEBluebird bio Inc